The familiar ‘Bolo Jubaan Kesari’ tagline from the Vimal Elaichi advertisement – featuring Bollywood stars Shah Rukh Khan, Ajay Devgn and Tiger Shroff throwing saffron – has landed the trio in regulatory hot water. The Maharashtra Food & Drug Administration (FDA) is questioning whether the campaign subtly promotes Vimal’s pan masala brand, despite its prohibition in Maharashtra.

At the heart of this investigation lies the concept of ‘surrogate advertising.’ Essentially, it's a marketing tactic where a company promotes a legally permissible product using branding elements associated with a restricted one. The FDA’s concern isn’t about the advertisement itself (cardamom is legal), but rather whether the presentation and messaging create an association with Vimal’s banned pan masala.

The Core of the Controversy: Surrogate Advertising

As explained Does seeing these popular actors promoting ‘Elaichi’ immediately trigger thoughts of Vimal’s brand? This tactic is often seen in industries where advertising for tobacco and alcohol products are heavily restricted – brands like Rajnigandha Pearls and Baba Elaichi have strategically built a visible presence around cardamom-based mouth fresheners to circumvent restrictions on their parent pan masala brands.

The FDA has issued formal notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff, requesting detailed explanations within 15 days. Their requests include submitting supporting documents and ceasing all participation in the Vimal Elaichi campaign immediately.

Specifically, the FDA is asking them to remove the advertisement from social media channels and refrain from any further promotional activities. The regulator also wants a full accounting of any agreements or contracts connected with their endorsement of the product.

This isn’t a finding of guilt – it's an investigation into whether the campaign inadvertently violates Maharashtra’s strict regulations surrounding tobacco products.

Read More: 5 Hallmark Movies to Watch When You Need a Christmas Escape

The Actors’ Response & The FDA's Demands

The ban on gutkha and pan masala containing tobacco or nicotine in Maharashtra, enforced since 2012, provides crucial context. The FDA isn't operating in a vacuum; it's responding to a clear legal mandate designed to protect public health.

Section 24 of the Food Safety and Standards Act, 2006, prohibits misleading advertisements relating to food products, while Section 53 carries penalties – up to Rs 10 lakh – for those involved in disseminating such deceptive marketing. The FDA’s scrutiny reflects this serious regulatory framework.

The Vimal Elaichi case isn't an isolated incident. Numerous other brands have employed similar strategies, often leveraging music CDs or packaged water under their names to maintain brand visibility while navigating advertising restrictions on alcohol and tobacco products. Examples include Imperial Blue’s use of music CDs and McDowell’s No.

1 promoting soda under its brand identity.

These tactics highlight a complex intersection between consumer branding, regulatory oversight, and marketing strategy. The debate surrounding surrogate advertising raises important questions about how consumers perceive brands, and whether seemingly innocuous promotions can unintentionally reinforce associations with restricted products.

The outcome of the FDA's investigation hinges on the actors' responses and supporting documentation. Ultimately, the regulator will determine if the Vimal Elaichi campaign constitutes a violation of Maharashtra’s food safety regulations – or simply a clever marketing strategy navigating a challenging landscape.